Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 729-734

  Ahmad, Zahoor ^a   Nuermberger, Eric L ^a,b   Tasneen, Rokeya ^a   Pinn, Michael L ^a   Williams, Kathy N ^a   Peloquin, Charles A ^c   Grosset, Jacques H ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Chemotherapy; Isoniazid; Mycobacterium tuberculosis; Persistence; Pyrazinamide; Rifampicin

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RELAPSE; TREATMENT DURATION; TUBERCULOSIS; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; LUNG; MICROBIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 77952572253     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq007     Document Type: Article

References (32)

1. Nuermberger E. Using animal models to develop new treatments for tuberculosis. Semin Respir Crit Care Med 2008; 29: 542-51.
2. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 1944; 55:66-9.
3. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-802.
4. Nuermberger EL, Yoshimatsu T, Tyagi S et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-6.
5. Rosenthal IM, Williams K, Tyagi S et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005; 172: 1457-62.
6. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92: 687-703.
7. Cohn DL, Catlin BJ, Peterson KL et al. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112: 407-15.
8. Karlson AG, Feldman WH. Isoniazid in experimental tuberculosis of guinea pigs infected with tubercle bacilli resistant to streptomycin and to para-aminosalicylic acid. Am Rev Tuberc 1952; 66: 477-85.
9. Karlson AG. Therapeutic effect of ethambutol (dextro-2,2′- (ethylenediimino)-di-1-butanol) on experimental tuberculosis in guinea pigs. Am Rev Respir Dis 1961; 84: 902-4.
10. Dickinson JM, Mitchison DA. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. Tubercle 1976; 57: 251-8.
11. Dickinson JM, Mitchison DA. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 1970; 51: 82-94.
12. Dickinson JM, Aber VR, Mitchison DA. Studies on the treatment of experimental tuberculosis of the guinea pig with intermittent doses of isoniazid. Tubercle 1973; 54: 211-24.
13. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005; 85: 227-34.
14. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005; 26: 298-303.
15. Ahmad Z, Klinkenberg LG, Pinn ML et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009; 200: 1136-43.
16. Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 2008; 61: 323-31.
17. Perlman DC, Segal Y, Rosenkranz S et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41: 1638-47.
18. Zhu M, Starke JR, Burman WJ et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22: 686-95.
19. Grosset J, Truffot-Pernot C, Lacroix C et al. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36: 548-51.
20. Jayaram R, Shandil RK, Gaonkar S et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
21. Chang KC, Leung CC, Yew WW et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: 1124-30.
22. Leibert E, Rom W. Principles of tuberculosis management. In: Rom W, Garay S, eds. Tuberculosis. 2nd edn. Philadelphia: Lippincott Williams and Wilkins, 2004; 713-28.
23. Palaci M, Dietze R, Hadad DJ et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 2007; 45: 4064-6.
24. A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1981; 124: 138-42.
25. Dutt AK, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am Rev Respir Dis 1989; 139: 867-70.
26. Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Ann Acad Med Singapore 2002; 31: 175-81.
27. Johnson JL, Hadad DJ, Dietze R et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180: 558-63.
28. Mitchison DA. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Semin Respir Crit Care Med 2004; 25: 307-15.
29. Grosset JH, Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria: Chemotherapy. New York: Chapman and Hall, 1998; 51-97.
30. Lenaerts AJ, Hoff D, Aly S et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007; 51: 3338-45.
31. Bartlett JG, Taylor NS, Chang T et al. Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr 1980; 33: 2521-6.
32. Williams KN, Brickner SJ, Stover CK et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009; 180: 371-6.